Posted 3 months ago

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)

ClinicalTrials.gov ID NCT06129864

Protocol number D798EC00001

Sponsor Astra Zeneca